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Acute kidney injury (AKI) is a serious complication in the perioperative period, and is consistently associated with
increased rates of mortality and morbidity. Two major consensus definitions have been developed in the last
decade that allow for easier comparison of trial evidence. Risk factors have been identified in both cardiac and
general surgery and there is an evolving role for novel biomarkers. Despite this, there has been no real change in
outcomes and the mainstay of treatment remains preventive with no clear evidence supporting any therapeutic
intervention as yet. This review focuses on definition, risk factors, the emerging role of biomarkers and subsequent
management of AKI in the perioperative period, taking into account new and emerging strategies.
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Introduction
Acute kidney injury (AKI) occurs in 1% to 5% of all hospital
admissions, and in the perioperative period has serious
implications, being consistently associated with (unaccept-
ably) high mortality, morbidity and a more complicated
hospital course with associated cost implications. This is
particularly the case when renal replacement therapy (RRT)
is required [1-22]. It is widely recognized that AKI requiring
dialysis is an independent risk factor for death [1-3]; more
recently, however, even minimal increases in serum creatin-
ine have been associated with an increase in both short and
long-term mortality, regardless of whether partial or full re-
covery of renal function has occurred at the time of dis-
charge [4-11]. This risk of death is independent from other
postoperative complications and co-morbidities [7-9]. AKI
is related to the subsequent development and progression
of chronic kidney disease (CKD) and the need for future
dialysis, most notably in those with a degree of pre-existing
renal impairment [11-15], but also in those who have ap-
parent recovery following an episode of AKI [7]. Despite an
increase in our knowledge of AKI and advances in other
relevant areas over the last two decades (including intensive
care, delivery of dialysis and surgical techniques), there have
been no significant changes in these outcomes [12,15-17].
As such, identification of risk factors, close monitoring of
renal function and early adoption of both preventive* Correspondence: andrew.shaw@duke.edu
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distribution, and reproduction in any mediummeasures and treatments remain important considera-
tions for those taking care of perioperative patients
who are likely to develop AKI.Incidence
Surgery remains a leading cause of AKI in hospitalized
patients (the incidence ranges from 18% to 47% depending
on the definition used) [17,18]. This has been best
researched in the cardiac surgery setting where it has been
shown that up to 15% of patients exposed to cardiopul-
monary bypass (CPB) will develop AKI, with 2% requiring
RRT [23]. Depending on the criteria used to define AKI
and the postoperative period studied, mortality ranges
from 1% to 30% [5,24] although this is consistently higher,
approaching 80%, if RRT is required [2,17,24]. AKI is not
limited to cardiac surgery although its incidence outside
of this setting is often underappreciated. Kheterpal et al.
demonstrated that in patients without pre-existing renal
disease, approximately 1% of major non-cardiac surgery
was complicated by AKI, with an eight-fold increase in
30-day mortality [20,23]. This incidence is comparable to
other notable postoperative complications including major
adverse cardiac events (MACE) and venous thrombo-
embolism [23].
In the intensive care setting, the Beginning and Ending
Supportive Therapy for the Kidney (BEST Kidney) inves-
tigators confirmed major surgery as the second leading
cause of AKI (in 34%) in this cohort of patients, with
overall hospital mortality of 60.3% [1]. Analysis of data
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showing surgical admissions accounted for 16.4% of
admissions with severe AKI in the first 24 hours (with
elective and emergency cases accounting for 5.6% and
10.8%, respectively). In that study, defining severe AKI
as creatinine >300 μmol/l and/or urea >40 mmol/l has
restricted the patient cohort and potentially, therefore,
may limit its generalizability [25]. Elsewhere, it has been
reported that one third of patients with AKI require a
critical care admission at some point in their care [14].
Definition
Although AKI has been the focus of much research over
the past decades, lack of a consensus definition has been
a major factor hampering clinical research and compari-
son of trial data [1,12,13,22,26,27]. There are now two
major classifications of AKI in use. The Acute Dialysis
Quality Initiative (ADQI) Group introduced the RIFLE
(Risk, Injury, Failure, Loss and End-stage) classification
system in 2004, which defines three grades of severity and
two outcomes, in an effort to standardize the definition
[7,12,28,29]. This has subsequently been validated in a
number of studies [7,29-35]. The Acute Kidney Injury
Network (AKIN) group proposed refinements to this cri-
teria, outlining AKI as abrupt (occurring within 48 hours)
and using a smaller change in serum creatinine from base-
line in patients who are optimally hydrated to define AKI
[12,28,29], following recognition of emerging evidence
demonstrating the clinical importance of small increasesTable 1 Classification of acute kidney injury by RIFLE, AKIN a
Stage Glomerular filtration rate (GFR) criteria
RIFLE classification
Risk Serum creatinine increased x 1.5 or GFR decre
Injury Serum creatinine increased x 2 or GFR decreas
Failure Serum creatinine increased x 3 or GFR decreas
serum creatinine≥ 354 μmol/L with an acute
Loss Persistent AKI, requiring RRT for> 4 weeks
End-stage kidney
disease
Requiring dialysis> 3 months
AKIN classification
Stage 1 Serum creatinine increased≥26.2 μmol/L or x
Stage 2 Serum creatinine increased x 2 to 3 baseline
Stage 3 Serum creatinine increased> x 3 baseline or s
creatinine≥ 354 μmol/L
with an acute rise≥ 44 μmol/L or initiation of
KDIGO classification
Stage 1 Serum creatinine increased x 1.5 to 1.9 baselin
Stage 2 Serum creatinine increased x 2 to 2.9 baseline
Stage 3 Serum creatinine increased> x 3 baseline or s
creatinine≥ 354 μmol/L
with an acute rise≥ 44 μmol/L or initiation of
AKIN, Acute Kidney Injury Network; KDIGO, Kidney Disease: Improving Global Outcomin serum creatinine [5-9]. No clear advantages between
these criteria have been demonstrated and despite these
recommendations, definitions of AKI continue to vary
[29]. The Kidney Disease: Improving Global Outcomes
(KDIGO) workgroup has recently reviewed these criteria
and published a single definition for use in both clinical
practice and research. AKI is defined when any of the fol-
lowing three criteria are met; an increase in serum
creatinine by 50% in seven days, an increase in serum
creatinine> 0.3 mg/dL in 48 hours or oliguria. The
severity is staged according the criteria outlined in
Table 1 [36].
Recognition is often still delayed and more recently,
the role of electronic reporting systems has been suc-
cessfully tested in the UK with the aim of alerting clini-
cians early to the presence of AKI, appreciating the
impact of small increases in creatinine from baseline
that previously may have been considered as fluctuations
remaining within the normal range. In turn, this should
allow for timely intervention and improved overall pa-
tient care [37].
RIFLE, AKIN and KDIGO all diagnose AKI according
to serum creatinine and urine output as outlined in
Table 1. This, however, is not without its limitations, as
serum creatinine is neither sensitive nor specific, tending
to represent a functional change rather than being a true
marker of kidney injury and is well known to be affected
by multiple factors including age, ethnicity, gender, muscle
mass, total body volume, medications and protein intakend KIDGO criteria [12,28,36]
Urine output criteria
ase >25% <0.5 ml/kg/hr for≥ 6 hours
e >50% <0.5 ml/kg/hr for≥ 12 hours
e≥ 75% or an absolute
rise≥ 4 μmol/L
<0.3 ml/kg/hr for≥ 24 hours or anuria
for ≥12 hours
0.5 to 2 baseline <0.5 ml/kg/hr for≥ 6hours
<0.5 ml/kg/hr for≥ 12 hours
erum
RRT
<0.3 ml/kg/hr for≥ 24 hours or anuria
for ≥12 hours
e or by≥ 26.2 μmol/L <0.5 ml/kg/hr for 6 to 12 hours
<0.5 ml/kg/hr for≥ 12 hours
erum
RRT
<0.3 ml/kg/hr for≥ 24 hours or anuria
for ≥12 hours
es.
Calvert and Shaw Perioperative Medicine 2012, 1:6 Page 3 of 11
http://www.perioperativemedicinejournal.com/content/1/1/6[16,38]. Given that a reduction in glomerular filtration rate
(GFR) greater than 50% can occur before this is reflected
in serum creatinine [16,39,40], the ability to detect AKI
prior to a change in serum creatinine would represent a
significant advance in the management of AKI. As such,
the American Society of Nephrology set identification and
characterization of biomarkers for AKI as a key research
area in 2005 [41].
Risk factors
There have been a number of studies investigating the risk
factors associated with the development of AKI, from
which several factors, both patient and procedure related,
have been consistently associated in both cardiac and
non-cardiac surgery (Table 2) [3,20,23,24,42-45]. Patient
related factors are often more strongly associated with
postoperative mortality than surgical factors. These in-
clude age, hypertension, diabetes mellitus, cardiac failure,
peripheral vascular disease, cerebrovascular disease and
pre-existing chronic kidney disease [3,23,24,42-44]. Per-
haps the most important of these is the latter, with rates of
AKI requiring dialysis approaching 30% in patients with
pre-existing kidney disease undergoing cardiac surgery
[7,17,24,42-44]. That said, there remain risk factors spe-
cific to certain types of surgery which are associated with
postoperative AKI, including prolonged CPB time, com-
bined valve and coronary artery bypass graft (CABG) sur-
gery, increased aortic cross-clamp time during vascular
surgery and increased intra-abdominal pressure in major
abdominal surgery [2,17,46]. Unsurprisingly, many of
these risk factors are associated with either poor renal per-
fusion or decreased renal reserve and few are correctable
prior to surgery.
Integral to improving outcomes, however, is the ability
to identify high risk patients, not only allowing for earlier
intervention and optimal subsequent management, butTable 2 Factors associated with the development of AKI
Patient related factors Surgical factors
Age Duration of surgery
Hypertension Intra-peritoneal surgery
Diabetes Mellitus Length of CPB
Chronic Obstructive Pulmonary Disease Cross clamp time
LVF, EF <40% Hemolysis (cardiac surgery)
Chronic kidney disease Hemodilution (cardiac surgery)





EF, ejection fraction; IABP, Intra-aortic balloon pump; LVF, left ventricular
function.also identification of cohorts of patients in which new
treatments can be studied. Several groups have, therefore,
sought to develop risk stratification indexes in both car-
diac and general surgery [23,24,42,45,47]. Kheterphal et al.
developed a General Surgery AKI Risk Index after evaluat-
ing almost 76,000 general surgical patients, which also
included a validation sample. A score is given for each pa-
tient, based on nine separate preoperative risk factors, fol-
lowing which patients are categorized into one of five
classes. Class I (determined by having zero to two risk fac-
tors) has an incidence of AKI of 0.2%; in contrast to Class
V (>6 risk factors) which confers an AKI risk of 9.5% [23].
Although useful in highlighting risk factors, further valid-
ation over multiple centers is crucial, with similar single
center risk scoring systems post-cardiac surgery having
been shown to underestimate the true incidence of AKI,
despite taking into account demographic variation [47].
Novel biomarkers
An ideal biomarker would be highly sensitive and spe-
cific for AKI, responding consistently and rapidly to in-
jury, with normal ranges for age, race and gender
established and levels that correlate to severity as well as
having biological stability and a reliable, quick and cost
effective assay for detection [48,49]. It would also be
useful to determine the extent of interpersonal variation
attributable to genetic factors and the impact of con-
founding clinical factors [48]. The area under the re-
ceiver-operating characteristic curve (AUCROC) is used
to assess the performance of a diagnostic biomarker,
with a value greater than 0.75 demonstrating good dis-
criminatory value and greater than 0.90 demonstrating
excellent discrimination.
A current challenge is that novel biomarkers are being
compared to serum creatinine as the ‘gold standard’
when it is the very weakness of serum creatinine as a
sensitive and specific marker that prompted research
into this area. Indeed, many authors have made this
exact point in their opening statements [50]. More than
20 different biomarkers have been identified in recent
years, predominantly in studies of post-cardiac surgery.
However, most current focus is on neutrophil gelatinase-
associated lipocalin (NGAL), kidney injury molecule− 1
(KIM-1), IL-18 and cystatin-C. At present these remain
experimental and need validation in larger studies prior
to transition into clinical practice [38]. It is highly likely
that several other biomarkers will also be introduced
into clinical practice over the next few years.
NGAL
NGAL has generated significant interest in recent years,
particularly in AKI following cardiac surgery, although
its use is not restricted to this cohort of patients [39,51-
53]. In patients with normal renal function, NGAL is
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mal studies clearly demonstrated that NGAL is markedly
upregulated early following ischemic injury [54]. In sub-
sequent clinical studies, urinary NGAL has been shown
to be both sensitive and specific in predicting postopera-
tive AKI in pediatric patients undergoing cardiac surgery
[43,51,52]. Similarly, plasma NGAL measured at two
hours post-CPB correlated strongly with severity and dur-
ation of AKI, with an AUCROC of 0.96, sensitivity of 0.84
and specificity of 0.94 [39]. In an adult population, this re-
sult has been less consistent [51,52] with Wagener et al.
demonstrating an AUCROC of 0.61 and sensitivity of 0.39
in urinary NGAL measured 18 hours post-surgery [52].
Likewise, raised plasma NGAL levels have been clearly
demonstrated in AKI following CPB surgery, however
again with a low sensitivity thereby limiting its use as a
single biomarker in the prediction of AKI [55]. It has been
proposed that this poor sensitivity may be in part due to
the current limitations of defining AKI using serum cre-
atinine [52], although it should also be noted that patients
who develop AKI also tend to have a longer CPB time. Al-
though this has been clearly demonstrated to be a risk fac-
tor, it also raises the possibility that NGAL (particularly
plasma NGAL) could actually reflect length of CPB/degree
of inflammation versus degree of kidney injury [39]. Many
of these studies have, however, excluded patients with pre-
existing renal dysfunction. A post-hoc subgroup analysis
has attempted to address this and although these results
must be interpreted with a degree of caution, they do show
that the use of urinary NGAL is significantly influenced by
pre-existing renal function, with no clear relationship be-
tween postoperative urinary NGAL and the development
of AKI in patients with a GFR< 60 ml/minute [56]. This
suggests that the relationship between NGAL and AKI is
complex and is likely to be different in the setting of CKD
[57].KIM-1
KIM-1 is a type 1 transmembrane glycoprotein, undetect-
able in normal kidney tissue, which has been shown to be
markedly upregulated following injury secondary to ische-
mia and nephrotoxins in a variety of both animal and
human studies, with a soluble form readily detectable in
the urine [58]. Early human studies demonstrated a clear
increase in KIM-1 protein expression at biopsy that corre-
lated with high urinary levels, detectable prior to cast for-
mation, following ischemic injury [58]. Since then, KIM-1
has been shown to be a highly sensitive marker for AKI in
patients undergoing cardiac surgery [59] and, alongside an-
other urinary biomarker, N-acetyl-β-(D)-glucosaminidase,
high levels have been associated with adverse outcomes in-
cluding the need for renal replacement therapy and death
[60].IL-18
The cytokine IL-18 has also been shown to be an early
biomarker for AKI in a variety of clinical situations, in-
cluding in patients with CKD [61-65]. Post-CPB surgery,
urinary IL-18 was detectable four to six hours post-
surgery, peaking at 12 hours with an AUCROC of 0.75
and remaining elevated over the next 24 to 28 hours
(AUCROC at 24 hours 0.75) [61]. In addition, there is a
correlation between peak levels and increased severity of
AKI and mortality [63,64]. Unsurprisingly, given the role
of IL-18 as a pro-inflammatory cytokine, levels are higher
in cohorts of patients with sepsis than in those without
[64].Cystatin C
Cystatin C is a cysteine protease inhibitor produced by
all nucleated cells. Given that it is freely filtered by
the glomerulus, undergoes almost complete tubular
reabsorption and is not secreted by renal tubules, it is
desirable as a marker of GFR [40,66-68]. However, serum
cystatin C levels have been shown to be affected by the
use of steroids, thyroid dysfunction, age, gender and CRP
independent of GFR [40,66,67]. A prospective study look-
ing at 72 patients undergoing cardiac surgery demon-
strated no clear association between AKI and plasma
cystatin C although an early and persistent increase in
urinary cystatin C was associated with AKI, and the level
excreted correlated with the severity of AKI. This suggests
that in this cohort of patients, urinary cystatin C may be
more useful [67].
Importantly, many studies to date have excluded
patients with CKD, who have been consistently demon-
strated to be at high risk for AKI in the perioperative
period [20] and these biomarkers must therefore first be
characterized over a range of baseline values, with more
information required to identify and explain clinical fac-
tors that may confound their performance in the peri-
operative period [38-40,51-57,67]. It is unlikely that any
single biomarker would be sufficient for accurate diagnosis
and risk stratification of AKI but rather that the way for-
ward would be to develop a panel of biomarkers which,
used in conjunction, would allow for assessment of disease
severity and risk alongside earlier diagnosis [40,49,59,61].
This faces its own challenges and as yet there is insuffi-
cient information as to which combinations to recom-
mend for use. More work is clearly needed in this area,
with the ultimate aim being earlier recognition of AKI,
thereby allowing for progress to be made in its subsequent
treatment.Pathophysiology of AKI
Etiologically, AKI is divided into pre-renal, intrinsic or
renal, and post-renal causes, in surgery representing 30%
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[17] (Table 3). Renal hypoperfusion is often the initial in-
sult in perioperative AKI, which importantly can lead to a
reduction in medullary blood flow [17,46,69]. The outer
medulla with its high metabolic demands (medullary oxy-
gen extraction approaches 90%) is particularly vulnerable
to both hypoperfusion and hypoxia, both in patients with
known CKD whose underlying reserve is reduced but also
in patients with normal preoperative renal function [69-71].
Interestingly, in acute respiratory distress syndrome
(ARDS) it is increasingly recognized that the disease
process, for example, pulmonary versus extra-pulmonary
causes, impacts the course of the disease and whether the
same could be said for AKI remains to be seen [72].
Animal models have been developed, predominantly
based on ischemia-reperfusion injury or drug-induced in-
jury, which have significantly improved our understanding
of AKI, especially with regard to the role of inflammation.
This is thought to be especially important in AKI
associated with CPB surgery [73]. In clinical practice,
ischemia-reperfusion injury can occur secondary to either
general hypoperfusion or specific actions, for example,
cross-clamping of the aorta in vascular surgery. Interven-
tions that are beneficial in animal models, however, have
not yet been shown to be effective in clinical practice
[74,75].
Histologically, there is still a paucity of information
available, in part due to the invasive nature of renal
biopsies that are often not undertaken in patients in
whom AKI is presumed secondary to pre-renal factors
[74]. In biopsies that have been obtained, and from post-
mortem findings, there is a clear disparity seen between
the clinical scenario and the pathological findings [74].
This, in turn, supports the concept of cytopathic hypoxia
leading to cellular shutdown versus cell necrosis or apop-
tosis [75].
Management of AKI
The goals in management of AKI include preservation of
existing renal function as well as prevention of acuteTable 3 Summary of causes of AKI defined etiologically
Pre-renal Intrinsic renal diseas
Hypovolemia, for example, hemorrhage,
diarrhea, vomiting
Ischemia from prolong
Hypotension, for example, sepsis Glomerular disease, fo
glomerulonephritis, TT




Impaired renal autoregulation, for example,





ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin recreptor blocker; C
thrombotic thrombocytopenic purpura.complications (hyperkalemia, acidosis, volume overload)
and the need for long-term renal replacement therapy.
Avoidance of AKI remains the cornerstone of manage-
ment while research continues into effective treatment
options.
Preventive measures
Fluids and goal directed therapy
Maintenance of normal renal perfusion is perhaps the
most important prophylactic measure, with 80% of
patients experiencing postoperative AKI having an epi-
sode of hemodynamic instability in the perioperative
period [17,46]. The use of fluids in this period is therefore
vital although this should be approached with caution as
there are equally important recognized postoperative
complications associated with excess fluid including poor
wound healing and increased duration of mechanical
ventilation [76,77]. There is increasing evidence that a
positive fluid balance in both surgical and critical care
patients is associated with an increase in intra-abdominal
hypertension which, in turn, has a detrimental effect on
renal function [77-79]. Furthermore, hyperchloremia is
often associated with over-zealous fluid resuscitation with
0.9% saline and has been associated with a decrease in
renal blood flow [77]. Importantly, studies comparing con-
servative versus liberal fluid strategies have not seen an in-
crease in the incidence in AKI or an increased need for
RRT in the conservative arms [77].
There has, however, been no randomized controlled
trial (RCT) directed at addressing the role of fluid hydra-
tion in the prevention of AKI in surgical patients [80]
and this task often falls to junior members of the team.
A targeted approach with titration to specified end-
points may in fact be more appropriate [77,81].
Goal directed therapy (GDT) is a strategy that involves
the use of fluids, packed red cells and inotropes to reach
target hemodynamic parameters including cardiac out-
put and oxygen delivery to prevent organ dysfunction
[46,82,83]. Many high risk surgical patients (both elective
and emergency) are admitted to the ICU in thee Post-renal
ed hypoperfusion Obstructive causes, for example, prostatic








CF, congestive cardiac failure; DIC, disseminated intravascular coagulation; TTP,
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GDT in this time period has been associated with fewer
complications (including AKI) and improved mortality
[84]. In 2009, a meta-analysis demonstrated that AKI is
significantly reduced by perioperative hemodynamic
optimization, whether done in the pre-, intra- or post-
operative period [46]. This is particularly relevant when
resources for pre-operative optimization are limited. Of
note, meeting physiological values was as ‘reno-protective’
as meeting supra-normal values, which itself may be asso-
ciated with other complications although this remains a
point of debate [46].
The use of sodium bicarbonate has been addressed in
cardiac surgery. Following on from work supporting the
use of urinary alkanization in contrast nephropathy, a
pilot RCT in 100 post-CPB surgical patients showed a
reduction in the incidence of AKI in patients receiving
sodium bicarbonate versus a placebo saline infusion al-
though no changes were demonstrated in either the
need for RRT or mortality [85]. Further trials in this area
are ongoing/promising.
Avoidance of nephrotoxic agents
A number of different medications commonly used in
the perioperative period have potentially harmful effects
on renal function. Angiotensin-converting enzyme inhi-
bitors (ACEi) and angiotensin receptor blockers (ARB)
and NSAIDs are among drugs known to affect renal
autoregulation. Whether or not to continue ACEi/ARB
in the perioperative period remains under debate al-
though a meta-analysis has shown ACEi confer no pro-
tective benefits in this time period [86].
NSAIDs can also cause interstitial nephritis and their as-
sociation with the development of AKI led to recommen-
dations from the Medicines and Healthcare Products
Regulatory Agency suggesting that they should be avoided
in all patients with hypovolemia and sepsis regardless of
renal function [87]. Antibiotics can lead to AKI by either
direct injury, for example aminoglycosides in high concen-
trations, thereby necessitating monitoring of drug levels,
or secondary to an acute interstitial nephritis, for example
penicillins, quinolones and cephalosporins.
The role of intravenous contrast in AKI is well recog-
nized and where its use is unavoidable, the minimum
possible dose should be given as well as using the newer
iso-osmolar and low-osmolar non-ionic contrast, now
recognized to be less toxic [88,89]. Surgery should be post-
poned in stable patients with contrast-induced AKI.
Whether oral N-acetylcysteine confers any protective
benefit in this situation remains controversial [90].
Hemodilution and transfusion in cardiac surgery
Specific to cardiac surgery, the roles of hemodilution
and transfusion have also been studied. There is aknown association between AKI and erythrocyte transfu-
sion in cardiac surgery [91-94]. More recently, a single
center study has both confirmed this and suggested that
the level of pre-operative anemia also has an impact,
being associated with a more pronounced increase in
the incidence of AKI [95]. There is, however, ongoing
work into the role of erythropoietin (EPO) in this set-
ting, with a small pilot trial confirming its effectiveness
although a larger trial is required before this could be
recommended [96]. Hemodilution is induced in the set-
ting of cardio-pulmonary bypass surgery, in theory de-
creasing blood viscosity and improving microcirculatory
flow in the presence of both hypoperfusion and
hypothermia. However, this has been associated with a
significant increase in the incidence of AKI and, as such,
current guidelines underline the importance of limiting
hemodilution, with the Society of Thoracic Surgeons
and the Society of Cardiovascular Anaesthesiologists
recommending maintenance of hematocrit >21% and
hemoglobin >7 g/dl [91,97-100].
Pharmacological interventions
There have been many attempts to find pharmacological
interventions in the management of AKI, with the on-
going challenge regarding the use of standard definitions
and end-points making it difficult to directly compare
trial evidence. Until recently there have been no drugs
that have consistently been demonstrated to confer
benefit, although there is now some emerging evidence
in the setting of cardiac surgery [80,86].
Dopamine
Dopamine has been extensively used and its place
debated over the years, with much of the early enthusi-
asm driven by the assumption that increased renal blood
flow seen with low-dose dopamine is beneficial in the
management of AKI [101-103]. A meta-analysis pub-
lished in 2001, however, demonstrated no benefit using
dopamine for either the prevention or treatment of AKI.
This recommendation followed identification and ana-
lysis of 58 studies, 24 of which reported the outcomes
reviewed (including 17 RCTs) [102]. This was further
supported in a systematic literature review, last updated
in 2008 [86].
Fenoldopam
Fenoldopam is a selective DA-1 agonist which to date
has had mixed results when used in the management of
AKI [80,104,105]. In cardiac surgery, however, fenoldo-
pam was shown to consistently reduce the need for RRT
and mortality, although its use is potentially complicated
by systemic hypotension [80,106]. This undesirable side
effect may be improved with the use of intra-renal infu-
sions, an innovative/emerging strategy which to date has
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information with a larger number of patients is required
[105].
Diuretics (furosemide/mannitol)
While use of diuretics may improve urine output in the
setting of acute kidney injury, again there is no evidence
to support that they confer any improvement in out-
comes measured (including need for RRT and mortality)
[80,101,107]. Furthermore, use of furosemide has been
shown to be not only ineffective but also detrimental,
associated with higher postoperative serum creatinine
levels in cardiac patients [80,102,108]. Of note, mannitol
is often added to the priming solution used in CPB sur-
gery. Although initially shown to confer some preventive
benefits in children undergoing CPB surgery, these
results have not been reproduced in repeat studies, with
a suggestion that mannitol is actually associated with
increased tubular injury when given in combination with
dopamine [81,106,108,109].
Atrial natriuretic peptide (ANP)
ANP is produced by cardiac atria in response to atrial dila-
tation and its properties as an endogenous diuretic and
natriuretic substance led to further evaluation of ANP as
another potential therapy. Early RCTs showed a benefit in
only a sub-group of oliguric patients which was not repro-
duced in follow up studies and systemic hypotension was
noted to be a complicating factor [110-113]. A significant
reduction in the need for RRT was, however, seen in post-
cardiac surgical patients with decompensated congestive
cardiac failure (CCF) who received low-dose infusions of
recombinant human ANP. Of note, the lower dose infu-
sion was associated with a decrease in the incidence of
systemic hypotension, which in itself may contribute to
the change in results seen [113,114]. Outside of cardiac
surgery, there is at present no perceived benefit with ANP
[80,114].
Nesiritide (recombinant human β natriuretic peptide)
Nesiritide is another cardiac natriuretic peptide that is
currently under evaluation. Initial results in both cardiac
and abdominal aneurysm repair surgery have shown po-
tential protective benefits with an overall reduction in
mortality, however, there is a possible association with
increased mortality in acutely decompensated heart fail-
ure [114-116]. Overall, nesiritide warrants further inves-
tigation before recommendations/conclusions can be
confidently made [114-116].
Theophylline
Theophylline, an adenosine antagonist, in theory is
proposed to preserve renal blood flow by attenuating
vasoconstriction of renal vessels [117,118]. Severalsmall studies have been conducted using theophylline
in contrast-induced nephropathy; however, a meta-
analysis in 2005 was inconclusive and recommended
that a RCT in this area with a defined hydration
protocol would be of benefit [117]. In the setting of
CPB surgery, an infusion of theophylline conferred no
benefit in reducing the incidence of AKI [118].N-acetylcysteine
The role of N-acetlycysteine, an antioxidant most com-
monly used to enhance formation of glutathione after
paracetamol overdose, has not been shown to confer any
protective benefits in the perioperative period [119,120].
As mentioned above, there may be some role for this
agent in contrast-induced nephropathy [90].Glycemic control
A landmark study in 2001 demonstrated tight glycemic
control and showed improved outcomes in an Intensive
Therapy Unit setting, with a 41% reduction in AKI requir-
ing RRT [121]. This has, therefore, sparked renewed focus
in this area; however, subsequent studies have not repro-
duced these benefits [122]. More recently, in cardiac sur-
gery, while severe intraoperative and early postoperative
hyperglycemia was associated with poorer outcomes (in-
cluding an increased incidence of AKI), incremental
decreases in mean glucose concentrations did not show
consistent improvements in outcomes [123]. Given the in-
consistent results seen, the concept of tight glycemic con-
trol needs further reassessment, with development of
strategies that focus on avoiding large variations in blood
glucose and hypoglycemia [122,123].Prophylactic RRT
There is currently insufficient evidence to support the
use of prophylactic RRT in high-risk patients undergoing
major surgery. Indeed it seems somewhat counterpro-
ductive to dialyze someone in order to prevent dialysis.
A single center study in which 44 patients were rando-
mized either to receive prophylactic dialysis or post-
operative dialysis if indicated did,,however, show both a
decrease in mortality (4.8% versus 30.4%) and in AKI re-
quiring RRT [124]. An effect size this large is statistically
very unlikely in practice. Similarly, in the setting of con-
trast nephropathy, a small single center RCT showed that
prophylactic hemofiltration was associated with a decrease
in both mortality and morbidity although these findings
are limited by the lack of standardized hydration protocols
and use of N-Acetyl Cysteine in this trial [125]. However,
more evidence is required before this invasive strategy can
be recommended.
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Many of the goals of modern treatment are to prevent
AKI; when established, however, RRT then plays an im-
portant role in the subsequent management, with approxi-
mately 15% of patients in intensive care with AKI
receiving dialysis [126]. Despite decades of research and
debate, this remains an area where there is no clear con-
sensus as to the optimal timing, modality or dose of RRT,
yet it is recognized as a significant factor affecting out-
come in critically ill patients [1,11,127,128]. Earlier studies
suggested a benefit to higher dose hemodialysis or hemo-
filtration [127] although this was not confirmed in follow
up studies and the debate rages on [128-131].
Conclusions
AKI is a serious and often under-appreciated complication
in the perioperative period, with even small rises in serum
creatinine associated with both increased morbidity and
mortality. The use of risk stratification indices should help
in the identification of high risk patients, useful both for
clinical practice and on-going research. Recent advances
have been made in the field of biomarkers although this
work has yet to be translated into clinical practice and the
mainstay of treatment remains preventive, aiming to keep
patients optimally hydrated while avoiding nephrotoxic
agents. There are no pharmacological agents yet with
proven benefits in the management of AKI although there
is some emerging evidence favoring the use of fenoldopam
and ANP in the setting of cardiac surgery, with novel
techniques in the delivery of agents helping to overcome
systemic side effects.
Abbreviations
ACEi: Angiotensin converting enzyme inhibitor; AKI: Acute kidney injury;
AKIN: Acute Kidney Injury Network; ANP: Atrial natriuretic peptide;
ARB: Angiotensin receptor blocker; ARDS: Acute respiratory distress
syndrome; AUCROC: Area under the receiver operating characteristic curve;
CABG: Coronary artery bypass graft; CCF: Congestive cardiac failure;
CKD: Chronic kidney disease; CPB: Cardiopulmonary bypass;
DIC: Disseminated intravascular coagulation; EF: Ejection fraction;
EPO: Erythropoietin; GDT: Goal directed therapy; GFR: Glomerular filtration
rate; IABP: Intra-aortic balloon pump; Il-18: Interleukin-18; KDIGO: Kidney
Disease Improving Global Outcomes; KIM-1: Kidney injury molecule-1;
LVF: Left ventricular function; MACE: Major adverse cardiac events;
NGAL: Neutrophil gelatinase-associated lipocalin; NSAIDs: Non-steroidal anti-
inflammatory drugs; RIFLE: Risk Injury, Failure, Loss and End-stage;
RCT: Randomized controlled trial; RRT: Renal replacement therapy;
TTP: Thrombotic thrombocytopenic purpura.
Competing interests
The authors declare that they have no competing interests.
Author details
1St George’s Hospital, London, SW17 0QT, UK. 2Dept of Anesthesiology and
Critical Care Medicine, Duke University Medical Center/Durham VAMC,
Durham, USA.
Authors' contributions
SC wrote the first draft. SC and AS edited and finalized the review. Both
authors read and approved the final manuscript.Received: 6 July 2012 Accepted: 4 July 2012
Published: 4 July 2012References
1. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz
M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C: Acute renal
failure in critically ill paitents: a multinational, multicenter study. JAMA
2005, 294:813–818.
2. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J: Independent
association between acute renal failure and mortality following cardiac
surgery. Am J Med 1998, 104:343–348.
3. Thaker CV, Kharat V, Blanck S, Leaonard AC: Acute kidney injury after
gastric bypass surgery. Clin J Am Soc Nephrol 2007, 2:426–430.
4. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G,
Stegeman CA: Immediate postoperative renal function deterioration
in cardiac surgical patients predicts in-hospital mortality and long-
term survival. J Am Soc Nephrol 2005, 16:195–200.
5. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W,
Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict
poor prognosis in patients after cardiothoracic surgery: a prospective
cohort study. J Am Soc Nephrol 2004, 15:1597–1605.
6. Ishani A, Nelson D, Clothier B, Schult T, Nugent S, Greer N, Slinin Y, Ensrud
KE: The magnitude of acute serum creatinine increase after cardiac
surgery and the risk of chronic kidney disease, progression of kidney
disease, and death. Arch Intern Med 2011, 171:226–233.
7. Hobson CE, Yavas S, Segal MS, Schold JD, Tribble CG, Layon AJ, Bihorac A:
Acute kidney injury is associated with increased long-term mortality
after cardiothoracic surgery. Circulation 2009, 119:2444–2453.
8. Bihorac A, Yavas S, Subbiah S, Hobson CE, Schold JD, Gabrielli A, Layon AJ,
Segal MS: Long term risk of mortality and acute kidney injury during
hospitalization after major surgery. Ann Surg 2009, 249:851–858.
9. Lafrance JP, Miller DR: Acute kidney injury associates with increased
long-term mortality. J Am Soc Nephrol 2010, 21:345–352.
10. Palevskky PM: Epidemiology of acute renal failure: the tip of the Iceberg.
Clin J Am Soc Nephrol 2006, 2006:6–7.
11. Mehta RL, Pascual MT, Soroko S, Savage BR, Himmelfarb J, Ikizler TA,
Paganini EP, Chertow GM: Spectrum of acute renal failure in the intensive
care unit: the PICARD experience. Kidney Int 2004, 66:1613–1621.
12. Mehta RL, Kellum JA, Shah AV, Molitoris BA, Ronco C, Warnock DG,
Levin A, the Acute Kidney Injury Network: Acute Kidney Injury Network:
report of an initiative to improve outcome in acute kidney injury. Crit Care
2007, 11:R31.
13. Metnitz PG, Krenn CG, Steltzer H, Lang T, Ploder J, Lenz K, Le Gall JR, Druml
W: Effect of acute renal failure requiring renal replacement therapy on
outcome in critically ill patients. Crit Care Med 2002, 30:2051–2058.
14. Liano F, Junco E, Pascual J, Madero R, Verde E: The spectrum of acute
renal failure in the intensive care unit compared with that seen in
other settings. The Madrid Acute Renal Failure Study Group. Kidney
Int 1998, 66:S16–S24.
15. Druml W: Long term prognosis of patients with acute renal failure: is
intensive care worth it? Intensive Care Med 2005, 31:1145–1147.
16. Mehta RL, Chertow GM: Acute renal failure definitions and classification:
time for change? J Am Soc Nephrol 2003, 14:2178–2187.
17. Carmichael P, Carmichael AR: Acute renal failure in the surgical setting.
ANZ J Surg 2003, 73:144–153.
18. Shusterman N, Strom BL, Murray TG, Morrison G, West SL, Maislin G: Risk
factors and outcome of hospital acquired acute renal failure. Clinical
epidemiologic study. Am J Med 1987, 83:65–71.
19. Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jabor BL: Epidemiology
and outcomes of acute renal failure in hospitalized patients: a national
survey. Clin J Am Soc Nephrol 2006, 1:43–51.
20. Kheterpal S, Tremper KK, Englesbe MJ, O’Reilly M, Shanks AM, Fetterman DM,
Rosenberg AL, Swartz RD: Predictors of postoperative acute renal failure
after noncardiac surgery in patients with previously normal renal
function. Anesthesiology 2007, 107:892–902.
21. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, Himmelfarb J,
Collins AJ: Incidence and mortality of acute renal failure in medicare
beneficiaries, 1992–2001. J Am Soc Nephrol 2006, 17:1135–1142.
22. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney
injury, mortality, length of stay, and costs in hospitalized patients. J Am
Soc Nephrol 2005, 16:3365–3370.
Calvert and Shaw Perioperative Medicine 2012, 1:6 Page 9 of 11
http://www.perioperativemedicinejournal.com/content/1/1/623. Kheterpal S, Tremper KK, Heung M, Rosenberg AL, Englesbe M, Shanks
AM, Campbell DA: Development and validation of an acute kidney
injury risk index for patients undergoing general surgery.
Anesthesiology 2009, 110:505–515.
24. Chertow GM, Lazarus M, Christiansen CL, Cook F, Hammermeister KE, Grover F,
Daley J: Preoperative renal risk stratification. Circulation 1997, 95:878–884.
25. Kolhe NV, Stevens PE, Crowe AV, Lipkin GW, Harrison DA: Case mix,
outcome and activity for patients with severe acute kidney injury during
the first 24 hours after admission to an adult general critical care unit:
application of predictive models from a secondary analysis of the
ICNARC Case Mix Programme database. Crit Care 2008, 12(Suppl 1):S2.
26. Bellomo R, Kellum JA, Ronco C: Defining acute renal failure: physiological
principles. Intensive Care Med 2006, 30:33–37.
27. Bellomo R, Kellum JA, Ronco C: Defining and classifying acute renal
failure: from advocacy to consensus and validation of the RIFLE criteria.
Intensive Care Med 2009, 11:409–413.
28. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure:
definition, outcome measures, animal models, fluid therapy and
information technology needs: the Second International Consensus
Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care
2004, 8:R204–R212.
29. Bagshaw SM, George C, Bellomo R: A comparison of the RIFLE and AKIN
criteria for acute kidney injury in critically ill patients. Nephrol Dial
Transplant 2008, 23:1569–1574.
30. Abosaif NY, Tolba YA, Heap M, Russel J, El Nahas AM: The outcome of
acute renal failure in the intensive care unit according to RIFLE: model
application, sensitivity, and predictability. Am J Kidney Dis 2005,
46:1038–1048.
31. Hoste EA, Clermont G, Kerston A, Ventataraman R, Angus DC, De Bacquer D,
Kellum JA: RIFLE criteria for acute kidney injury are associated with
hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006,
10:R73.
32. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettila V: Acute renal failure after
cardiac surgery: evaluation of the RIFLE criteria. Ann Thorac Surg 2006,
81:542–546.
33. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C: An assessment of
RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med
2006, 34:1913–1917.
34. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit
according to RIFLE. Crit Care Med 2007, 35:1837–1845.
35. O’Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ:
Acute renal disease, as defined by the RIFLE criteria, post-liver
transplantation. Am J Transplant 2007, 7:168–176.
36. Disease K, Improving Global Outcomes (KDIGO) Acute Kidney Injury Work
Group: KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Kidney
Int Suppl 2012, 2:1–138.
37. Selby NM, Crowley L, Fluck RJ, McIntyre CW, Monaghan J, Lawson H, Kohle
NV: Use of electronic results reporting to diagnose and monitor AKI in
hospitalized patients. Clin J Am Soc Nephrol 2012, 7:533–540.
38. Coca SG, Yalavarthy R, Concato J, Parikh CR: Biomarkers for the diagnosis
and risk stratification of acute kidney injury: a systematic review. Kidney
Int 2007, 73:1008–1016.
39. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P:
Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney
injury, morbidity and mortality after pediatric cardiac surgery: a
prospective uncontrolled cohort study. Crit Care 2007, 11:R127.
40. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Petruck F, Janssen O,
Philipp T, Kribben A: Early detection of acute renal failure by serum
cystatin C. Kidney Int 2004, 66:1115–1122.
41. American Society of Nephrology Renal Research Report. J Am Soc Nephrol
2005, 16:1886–1890.
42. Thakar CV, Arrigain S, Worley S, Yared JP, Paganini EP: A clinical score to
predict acute renal failure after cardiac surgery. J Am Soc Nephrol 2005,
16:162–168.
43. Fortescue EB, Bates DW, Chertow GM: Predicting acute renal failure after
coronary bypass surgery: cross-validation of two risk stratification
algorithms. Kidney Int 2000, 57:2594–2602.
44. Thakar CV, Liangos O, Yared J-P, Nelson DA, Hariachar S, Paganini EP:
Validation and re-definition of a risk stratification algorithm. Hemodial Int
2003, 7:143–147.45. Eriksen BO, Hoff KRS, Solberg S: Prediction of acute renal failure after
cardiac surgery: retrospective cross-validation of a clinical algorithm.
Nephrol Dial Transplant 2003, 18:77–81.
46. Brienza N, Giglio MT, Marucci M, Fiore T: Does perioperative hemodynamic
optimization protect renal function in surgical patients? A meta-analytic
study. Crit Care Med 2009, 37:2079–2090.
47. Candela-Toha A, Elias-Martin E, Abraira V, Tenorio MT, Parise D, de Pablo A,
Centella T, Liano F: Predicting acute renal failure after cardiac surgery:
external validation of two new clinical scores. Clin J Am Soc Neprhol 2008,
3:1260–1265.
48. Mayeux R: Biomarkers: potential uses and limitations. NeuroRx 2004,
1:182–188.
49. Ray P, Yannick M, Riou B, Houle T: Statistical evaluation of a biomarker.
Anesthesiology 2010, 112:1023–1040.
50. Waiker SS, Betensky RA, Bonventre JV: Creatinine as the gold standard for
kidney injury biomarker studies? Nephrol Dial Transplant 2009,
124:3263–3265.
51. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi
K, Shao M, Bean J, Mori K, Barasch J, Devarajan P: Neutrophil gelatinase-
associated lipocalin (NGAL) as a biomarker for acute renal failure after
cardiac surgery. Lancet 2005, 365:1231–1238.
52. Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT: Urinary
neutrophil gelatinase-associated lipocalin and acute kidney injury after
cardiac surgery. Am J Kidney Dis 2008, 52:425–433.
53. Hirch R, Dent C, Pfriem H, Allen J, Beekman RH, Ma Q, Bennett M, Mitsnefes
M, Devarajan P: NGAL is an early predictive biomarker of contrast-
induced nephropathy in children. Pediatr Nephrol 2007, 22:2089–2095.
54. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan
P: Identification of neutrophil gelatinase-associated lipocalin as a novel
early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003,
14:2534–2543.
55. Perry TE, Muehlschlegel JD, Liu KY, Fax AA, Collard CD, Shernan SK, Body SC
for the CABG Genomics Investigators: Plasma neutrophil gelatinase-
associated lipocalin and acute postoperative kidney injury in adult
cardiac surgical patients. Anesth Analg 2010, 110:1541–1547.
56. Koyner JL, Vaidya VS, Bennett MR, Ma Q, Worcester E, Akhtar SA, Raman J,
Jeevanandam V, O’Connor MF, Devarajan P, Bonventre JV, Murray PT:
Urinary biomarkers in the clinical prognosis and early detection of acute
kidney injury. Clin J Am Soc Nephrol 2010, 5:2154–2165.
57. McIlroy DR, Wagener G, Lee TH: Neutrophil gelatinase-associated lipocalin
and acute kidney injury after cardiac surgery: the effect of baseline renal
function on diagnostic performance. Clin J Am Soc Nephrol 2010,
5:211–219.
58. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV: Kidney injury
molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule
injury. Kidney Int 2002, 62:237–244.
59. Han WK, Waikar SS, Johnson A, Betensky RA, Dent CL, Deverajan P,
Bonventre JV: Urinary biomarkers in the early diagnosis of acute kidney
injury. Kidney Int 2008, 73:863–869.
60. Liangos O, Perianayagam MC, Vaidya VS, Han WK, Wald R, Tighiouart H,
MacKinnon RW, Li L, Balakrishnan VS, Pereira BJG, Bonventre JV, Jaber BL:
Urinary N-acetyl-β-(D)-glucosaminidase activity and kidney injury
molecule-1 level are associated with adverse outcomes in acute renal
failure. J Am Soc Nephrol 2007, 18:904–912.
61. Parikh CR, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent
C, Deverajan P, Edelstein CL: Urinary IL-18 is an early predictive
biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006,
70:199–203.
62. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL: Urinary
interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney
Dis 2004, 43:405–414.
63. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL: Urine IL-18 is an early
diagnostic marker for acute kidney injury and predicts mortality in the
intensive care unit. J Am Soc Nephrol 2005, 16:3046–3052.
64. Washburn KK, Zappitelli M, Arikan AA, Lofis L, Yalavarthy R, Parikh CR,
Edelstein CL, Goldstein SL: Urinary interleukin-18 is an acute kidney injury
biomarker in critically ill children. Nephrol Dial Transplant 2008, 23:
566–572.
65. Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, Edelsteinn CL, Deverajan
P: Urine NGAL and IL-18 are predictive biomarkers for delayed graft
Calvert and Shaw Perioperative Medicine 2012, 1:6 Page 10 of 11
http://www.perioperativemedicinejournal.com/content/1/1/6function following kidney transplantation. Am J Transplant 2006,
6:1639–1645.
66. Wald R, Liangos O, Perianayagam MC, Kolyada A, Herget-Rosenthal S, Mazer
CD, Jaber BL: Plasma cystatin C and acute kidney injury after
cardiopulmonary bypass. Clin J Am Soc Nephrol 2010, 5:1373–1379.
67. Koyner JL, Bennet MR, Worcester EM, Ma Q, Raman J, Jeevanadam V, Kasza
KE, O’Connor MF, Konczal DJ, Trevino S, Devarajan P, Murray PT: Urinary
cystatin C as an early biomarker of acute kidney injury following adult
cardiothoracic surgery. Kidney Int 2008, 74:1059–1069.
68. Dharnidharka VR, Kown C, Stevens G: Serum cystatin C is superior to
serum creatinine as a marker of kidney function: a meta-analysis. Am J
Kidney Disease 2002, 40:221–226.
69. Redfors B, Bragadottir G, Sellgren J, Sward K, Rickstein SE: Acute renal
failure is NOT an “acute renal success” – a clinical study on the renal
oxygen supply/demand relationship in acute kidney injury. Crit Care Med
2010, 38:1695–1701.
70. Brezis M, Rosen S, Silva P, Epstein FH: Renal ischemia: a new perspective.
Kidney Int 1984, 26:375–383.
71. Bonventre JV, Weinberg JM: Recent advances in the pathophysiology of
ischemic acute renal failure. J Am Soc Nephrol 2003, 14:2199–2210.
72. Callister MEJ, Evans TW: Pulmonary vs extra-pulmonary ARDS: different
disease or just a useful concept. Curr Opin Crit Care 2002, 8:21–25.
73. Okusa MD: The inflammatory cascade in acute ischemic renal failure.
Nephron 2002, 90:133–138.
74. Wan L, Bellomo R, Giantomasso DD, Ronco C: The pathogenesis of septic
acute renal failure. Curr Opin Crit Care 2003, 9:496–502.
75. Fink MP: Cytopathic hypoxia. Is oxygen use impaired in sepsis as a result
of an acquired intrinsic derangement in cellular respiration? Crit Care Clin
2002, 18:165–175.
76. Rahbari NN, Zimmermann JB, Schmidt T, Koch M, Weigand MA, Weitz J:
Meta-analysis of standard, restrictive and supplemental fluid
administration in colorectal surgery. Br J Surg 2009, 96:331–341.
77. Prowle JR, Echeverri JE, Ligabo EV, Ronco C, Bellomo R: Fluid balance and
acute kidney injury. Nat Rev Nephrol 2010, 6:107–115.
78. Sugrue M, Jones F, Deane SAG, Bauman A, Hillman K: Intra-abdominal
hypertension is an independent cause of post-operative renal
impairment. Arch Surg 1999, 134:1082–1085.
79. McNelis J, Marini CP, Jurkiwicz A, Fields S, Caplin D, Stein D, Ritter G, Nathan
I, Simms H: Predictive factors associated with the development of
abdominal compartment syndrome in the surgical intensive care unit.
Arch Surg 2002, 137:133–136.
80. Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore P, Oudemas-van
Straated HM, Ronco C, Schetz MRC, Wottiez AJ: Prevention of acute kidney
injury and protection of renal function in ITU. Intensive Care Med 2010,
36:392–411.
81. Chappell D, Matthias J, Hofmann-Kiefer K, Conzen P, Rehm M: A rational
approach to perioperative fluid management. Anesthesiology 2008,
109:723–740.
82. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett EDl: Early
goal-directed therapy after major surgery reduces complications and
duration of hospital stay. A randomized controlled trial. Crit Care 2005, 9:
R687–R693.
83. Shoemaker WC, Appel PL, Kram HB: Hemodynamic and oxygen transport
responses in survivors and non-survivors of high-risk surgery. Crit Care
Med 1993, 21:977–990.
84. Rhodes A, Cecconi M, Hamilton M, Poloniecki J, Woods J, Boyd O, Bennett
D, Grounds RM: Goal-directed therapy in high-risk surgical patients:
a 15-year follow-up study. Intensive Care Med 2010, 36:1327–1332.
85. Haase M, Haase-Fielitz A, Bellomo R, Devararjan P, Story D, Matalanis G,
Reade MC, Bagshaw SM, Seevanayagam N, Seevanayagam S, Doolan L,
Buxton B, Dragun D: Sodium bicarbonate to prevent increases in serum
creatinine after cardiac surgery: a pilot double-blind, randomized
controlled trial. Crit Care Med 2009, 37:39–47.
86. Zacharias M, Conlon NP, Herbison GP, Sivalingam P, Hovhannisyan K:
Interventions for preventing renal function in the perioperative period.
Cochrane Database Syst Rev 2008, 8(4) CD003590.
87. Medicines and Healthcare Products Regulatory Agency: Non-steroidal anti-
inflammatory drugs: reminder on renal failure and impairment. www.mhra.
gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON088004.
88. McCullough PA, Soman SS: Contrast induced nephropathy. Crit Care Clin
2005, 21:261–280.89. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ, NEPHRIC
Study Investigators: Nephrotoxic effects in high-risk patients undergoing
angiography. N Engl J Med 2003, 348:491–499.
90. Brigouri C, Colombo A, Violante A, Balastrieri P, Manganelli F, Paolo Elia P,
Golia B, Lepore S, Riviezzo G, Scarpato P, Focaccio A, Librera M, Bonizzoni E,
Ricciardelli B: Standard vs double dose of N-acetylcysteine to prevent
contrast agent associated nephrotoxicity. Eur Heart J 2004, 25:206–211.
91. Habib RH, Zacharias A, Schwann TA: Role of hemodilutional anemia and
transfusion during cardiopulmonary bypass in renal injury after coronary
revascularization: implications on operative outcomes. Crit Care Med 2005,
33:1749–1756.
92. Kartouki K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M,
Dupuis JY, Fremes SE, Kent B, Laflamme C, Lamy A, Legare JF, Mazer CD,
McCLuskey SA, Rubens FD, Sawchuk C, Beattie WS: Acute kidney injury
after cardiac surgery: focus on modifiable risk factors. Circulation 2009,
119:495–502.
93. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD:
Increased mortality, postoperative morbidity, and cost after red blood
cell transfusion in patients having cardiac surgery. Circulation 2007,
116:2544–2552.
94. Kartouki K, Wijeysundera DN, Beattie WS: Risk associated with preoperative
anemia in cardiac surgery: a multicenter cohort study. Circulation 2008,
117:478–484.
95. Kartouki K, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wony PY,
Beattie WS: Influence of erythrocyte transfusion on the risk of acute
kidney injury after cardiac surgery differs in anemic and nonanemic
patients. Anesthesiology 2011, 115:523–530.
96. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH,
Na KY: Prevention of acute kidney injury by erythropoietin in patients
undergoing coronary artery bypass gratfing: a pilot study.
Am J Nephrol 2009, 30:253–260.
97. Swaminathan M, Phillips-Bute BG, Conlon PJ, Smith PK, Newman MF,
Stafford-Smith M: The association of lowest hematocrit during
cardiopulmonary bypass surgery with acute renal failure after coronary
artery bypass surgery. Ann Thorac Surg 2003, 76:784–792.
98. Karkouti K, Beattie WS, Wijeysundera DN, Rao V, Chan C, Dattilo KM, Djaiani
G, Ivanon J, Karski J, David TE: Hemodilution during cardiopulmonary
bypass is an independent risk factor for acute renal failure in adult
cardiac surgery. J Thorac Cardiovasc Surg 2005, 129:391–400.
99. Society of Thoracic Surgeons Blood Conservation Guideline Task Force,
Ferraris VA, Ferraris SP, Saha SP, Hessel EA, Haan CK, Royston BD,
Bridges CR, Higgins RS, Despotis G, Brown JR, Society of Cardiovascular
Anaesthesiologists Special Task Force on Blood Transfusion, Speiss BD,
Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E,
Hill E, Body S: Perioperative blood transfusion and blood conservation in
cardiac surgery: the Society of Thoracic Surgeons and The Society of
Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac
Surg 2007, 83:S27–S86.
100. Vretzakis G, Kleitsaki A, Stamoulis K, Bareka M, Georgopoulou S, Karanikolas
M, Giannoulas A: Intra-operative intravenous fluid restriction reduces
perioperative red blood cell transfusion in elective cardiac surgery,
especially in transfusion-prone patients: a prospective, randomized
controlled trial. J Cardiothorac Surg 2010, 5:7.
101. Lassnigg A, Donner E, Grubhofer G, Presterl E, Druml W, Hiesmayr M: Lack
of renoprotective effects of dopamine and furosemide during cardiac
surgery. J Am Soc Nephrol 2000, 11:97–104.
102. Carcoana OV, Hines RL: Is renal dose dopamine protective or therapeutic?
Yes. Crit Care Clin 1996, 12:677–685.
103. Kellum JA, Decker JM: Use of dopamine in acute renal failure:
A meta-analysis. Crit Care Med 2001, 29:1526–1531.
104. Landoni G, Biondi-Zoccai GG, Marino G, Bove T, Fochi O, Maj G, Calabro MG,
Sheiban I, Tumlin JA, Ranucci M, Zangrillo A: Fenoldopam reduces the
need for renal replacement therapy and in-hospital death in
cardiovascular surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2008,
22:27–33.
105. Ng MK, Tremmel J, Fitzgerald PJ, Fearon WF: Selective renal arterial
infusion of fenoldopam for the prevention of contrast-induced
nephropathy. J Interv Cardiol 2006, 19:75–79.
106. Carcoana OV, Mathew JP, David E, Byrne DW, Hayslett JP, Hines RL, Garwood
S: Mannitol and dopamine in patients undergoing cardiopulmonary
bypass: A randomized clinical trial. Anesth Analg 2003, 97:1222–1229.
Calvert and Shaw Perioperative Medicine 2012, 1:6 Page 11 of 11
http://www.perioperativemedicinejournal.com/content/1/1/6107. Sirivella S, Gielchinsky I, Parsonnet V: Mannitol, furosemide, and dopamine
infusion in postoperative renal failure complicating cardiac surgery. Ann
Thorac Surg 2000, 69:501–506.
108. Van der Voort PHJ, Boerma EC, Koopmans M, Zandberg M, de Ruiter J,
Gerritsen RT, Egbers PH, Kingma WP, Kuiper MA: Furosemide does not
improve renal recovery after hemofiltration for acute renal failure: a
double blind randomized controlled trial. Crit Care Med 2009, 37:533–538.
109. Rigden SP, Dillon MJ, Kind PR, de Leval M, Stark J, Barratt TM: The beneficial
effect of mannitol on postoperative renal function in children
undergoing cardiopulmonary bypass surgery. Clin Nephrol 1984,
21:148–151.
110. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA,
Sweet RM, Genter FC, Kurnik BR, Conger JD, Sayegh MH: Anaritide in acute
tubular necrosis: Auriculin Anaritide Acute Renal Failure Study Group. N
Engl J Med 1997, 336:828–834.
111. Lewis J, Salem MM, Chertow GM, Weidberg LS, McGrew F, Marbury TC,
Allgren RL: Atrial natriuretic factor in oliguric acute renal failure. Anaritide
Acute Renal Failure Study Group. Am J Kidney Dis 2000, 36:767–774.
112. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW,
Conger JD: Effects of atrial natriuretic peptide in clinical acute renal
failure. Kidney Int 1994, 45:1731–1738.
113. Sward K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE: Recombinant
human atrial natriuretic peptide in ischemic acute renal failure: a
randomized placebo-controlled trial. Crit Care Med 2004, 32:1310–1315.
114. Nigewaker SU, Navaneethan SD, Parikh CR, Hix JK: Atrial natriuretic peptide
for management of acute kidney injury: a systematic review and meta-
analysis. Clin J Am Soc Nephrol 2009, 4:261–272.
115. Mentzer RM, Oz MC, Sladen RC, Graeve AH, Hebeler RF Jr, Luber JM Jr,
Smedira NG, NAPA Investigators: Effects of perioperative nesiritide in
patients with left ventricular dysfunction undergoing cardiac surgery:
The NAPA trial. J Am Coll Cardiol 2007, 49:716–726.
116. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of
death after treatment with nesiritide for decompensated heart failure: a
pooled analysis of randomized controlled trials. JAMA 2005,
293:1900–1905.
117. Bagshaw SM, Ghali A: Theophylline for prevention of contrast-induced
nephrology. Arch Intern Med 2005, 165:1087–1093.
118. Kramer BK, Preuner J, Ebenburger A, Kaiser M, Bergner U, Eilles C, Kammerl
MC, Riegger GAJ, Birnbaum DE: Lack of renoprotective effect of
theophylline during aortocoronary bypass surgery. Nephrol Dial Transplant
2002, 17:910–915.
119. Adabag AS, Ishani A, Bloomfoeld HE, Ngo AK, Wilt TJ: Efficacy of N-
acetylcysteine in preventing renal injury after heart surgery: a systematic
review of randomized trials. Eur Heart Journal 2009, 30:1910–1917.
120. Nigwekar SU, Kandula P: N-acetylcysteine in cardiovascular-surgery-
associated renal failure: a meta-analysis. Ann Thorac Surg 2009,
87:139–147.
121. Van de Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M,
Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy
in critically ill patients. N Engl J Med 2001, 345:1359–1367.
122. Lena D, Kalfon P, Preiser JC, Ichai C: Glycemic control in the Intensive Care
Unit and during the postoperative period. Anesthesiology 2011,
114:438–444.
123. Duncan AE, Abd-Elsayed A, Maheshwari A, Xu M, Soltesz E, Koch CG: Role of
intraoperative and postoperative blood glucose concentrations in
predicting outcomes after cardiac surgery. Anesthesiology 2010,
112:860–871.
124. Durmaz I, Yagdi T, Calkavur T, Mahmudiv R, Apaydon AZ, Posacioglu H, Atay
Y, Engin C: Prophylactic dialysis in patients with renal dysfunction
undergoing on-pump coronary artery bypass surgery. Ann Thorac Surg
2003, 75:859–864.
125. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni
D, Fabiocchi F, Montorsi P, Bartorelli AL: The prevention of radiocontrast-
agent-induced nephropathy by hemofiltration. N Eng J Med 2003,
349:1333–1340.
126. Ostermann M, Chang R: Correlation between the AKI classification and
outcome. Crit Care 2008, 12:R144.
127. Granado RC, Mehta RL: Assessing and delivering dialysis dose in acute
kidney injury. Semin Dial 2011, 24:157–163.
128. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G:
Effects of different doses in continuous veno-venous haemofiltration onoutcomes of acute renal failure: A prospective randomised trial. Lancet
2000, 356:26–30.
129. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille KM: Standard
versus high dose CVVHDF for ICU-related acute renal failure. J Am Soc
Nephrol 2008, 19:1233–1238.
130. Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, McArthur C,
McGuiness S, Myburgh J, Norton R, Scheinkestel C, Su S: Intensity of
continuous renal replacement therapy in critically ill patients. N Engl J
Med 2009, 361:1627–1638.
131. Palevsky PM, Zhang JH, O’Connor TZ, Chertow GM, Crowley ST, Choudhury
D, Finkel K, Kellum JA, Paganini E, Schein RM, Smith MW, Swanson KM,
Thompson BT, Vijayan A, Watnick S, Star RA, Peduzzi P: Intensity of renal
support in critically ill patients with acute kidney injury. N Engl J Med
2008, 359:7–20.
doi:10.1186/2047-0525-1-6
Cite this article as: Calvert and Shaw: Perioperative acute kidney injury.
Perioperative Medicine 2012 1:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
